ATE453382T1 - Pulver zur nasalen verabreichung von wirkstoffen - Google Patents

Pulver zur nasalen verabreichung von wirkstoffen

Info

Publication number
ATE453382T1
ATE453382T1 AT02801894T AT02801894T ATE453382T1 AT E453382 T1 ATE453382 T1 AT E453382T1 AT 02801894 T AT02801894 T AT 02801894T AT 02801894 T AT02801894 T AT 02801894T AT E453382 T1 ATE453382 T1 AT E453382T1
Authority
AT
Austria
Prior art keywords
nasal administration
powder
active ingredients
formulae
present
Prior art date
Application number
AT02801894T
Other languages
English (en)
Inventor
Paolo Colombo
Patrizia Santi
Ruggero Bettini
Pier Catellani
Mariella Artusi
Cecilia Sacchetti
Original Assignee
Univ Parma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Parma filed Critical Univ Parma
Application granted granted Critical
Publication of ATE453382T1 publication Critical patent/ATE453382T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02801894T 2001-10-18 2002-10-17 Pulver zur nasalen verabreichung von wirkstoffen ATE453382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002174A ITMI20012174A1 (it) 2001-10-18 2001-10-18 Polvere per somministrazione nasale di farmaci
PCT/EP2002/011628 WO2003035034A2 (en) 2001-10-18 2002-10-17 Powder for nasal administration of drugs

Publications (1)

Publication Number Publication Date
ATE453382T1 true ATE453382T1 (de) 2010-01-15

Family

ID=11448525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801894T ATE453382T1 (de) 2001-10-18 2002-10-17 Pulver zur nasalen verabreichung von wirkstoffen

Country Status (7)

Country Link
US (1) US20050019411A1 (de)
EP (1) EP1441699B1 (de)
AT (1) ATE453382T1 (de)
AU (1) AU2002357457A1 (de)
DE (1) DE60234945D1 (de)
IT (1) ITMI20012174A1 (de)
WO (1) WO2003035034A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20100233276A1 (en) * 2007-10-26 2010-09-16 Universita' Degli Studi Di Parma Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
WO2017146994A1 (en) * 2016-02-24 2017-08-31 Merck Sharp & Dohme Corp. Controlled agglomeration of micronized drug or drug-excipient mixtures
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
BR112022023307A2 (pt) 2020-05-18 2022-12-20 Orexo Ab Composição farmacêutica para entrega de fármacos
EP3991573A1 (de) 2020-11-03 2022-05-04 Patrick Faber Zusammensetzungen zur nasalen applikation
EP4236921A1 (de) 2021-11-25 2023-09-06 Orexo AB Adrenalin enthaltende pharmazeutische zusammensetzung
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
CN1149076C (zh) * 1997-03-20 2004-05-12 先灵公司 粉末附聚物的制备方法
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CN1283991A (zh) * 1997-12-03 2001-02-14 藤泽药品工业株式会社 软质颗粒状药剂以及它的制造方法
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e

Also Published As

Publication number Publication date
WO2003035034A2 (en) 2003-05-01
AU2002357457A1 (en) 2003-05-06
ITMI20012174A1 (it) 2003-04-18
EP1441699B1 (de) 2009-12-30
WO2003035034A3 (en) 2004-03-11
DE60234945D1 (de) 2010-02-11
EP1441699A2 (de) 2004-08-04
US20050019411A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
ATE453382T1 (de) Pulver zur nasalen verabreichung von wirkstoffen
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
HK1086832A1 (en) Substituted benzosulphonamides as potentiators of glutamate receptors
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
PL371736A1 (en) Method for administering glp-1 molecules
TNSN05180A1 (en) Liquid pharmaceutical formulations of palonosetron
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
SE0103211D0 (sv) New formulations and use thereof
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
GB0320020D0 (en) Improved formulation for providing an enteric coating material
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
SI1433478T1 (sl) Farmacevtske formulacije za tiroidne hormone in postopki za njihovo pripravo
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
WO2003060066A3 (en) Nucleic acid delivery and expression
WO2005123113A3 (en) Interferon compositions and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties